The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Acerta Pharma/AstraZeneca; BeiGene; Janssen-Cilag; LOXO; Merck; TG Therapeutics
Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).
 
Wojciech Jurczak
No Relationships to Disclose
 
Pier Luigi Zinzani
No Relationships to Disclose
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Roche (Inst)
 
Sharon Yavrom
Employment - Aduro Biotech; MEI Pharma
Stock and Other Ownership Interests - Aduro Biotech; MEI Pharma
 
Wenying Huang
Employment - MEI Pharma
Consulting or Advisory Role - Amgen
 
Igor Gorbatchevsky
Employment - Bayer; Iovance Biotherapeutics; MEI Pharma
 
Vincent Ribrag
No Relationships to Disclose